Prestige Consumer Healthcare (NYSE:PBH) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Prestige Consumer Healthcare (NYSE:PBH – Get Rating) in a research note published on Thursday. The brokerage issued a buy rating on the stock.

Other analysts also recently issued reports about the company. Canaccord Genuity Group began coverage on Prestige Consumer Healthcare in a research note on Wednesday, November 16th. They set a buy rating and a $71.00 price objective for the company. Canaccord Genuity Group began coverage on Prestige Consumer Healthcare in a research report on Thursday, November 17th. They set a buy rating and a $71.00 target price on the stock. Finally, Oppenheimer dropped their target price on Prestige Consumer Healthcare from $72.00 to $71.00 and set an outperform rating on the stock in a research report on Friday, February 17th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $77.40.

Prestige Consumer Healthcare Stock Down 0.8 %

PBH opened at $61.28 on Thursday. The business has a 50 day moving average price of $62.42 and a two-hundred day moving average price of $58.38. The company has a quick ratio of 1.56, a current ratio of 2.55 and a debt-to-equity ratio of 0.85. The company has a market cap of $3.05 billion, a PE ratio of 14.70, a P/E/G ratio of 1.85 and a beta of 0.56. Prestige Consumer Healthcare has a 52 week low of $48.51 and a 52 week high of $67.45.

Prestige Consumer Healthcare (NYSE:PBH – Get Rating) last posted its quarterly earnings data on Thursday, February 2nd. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $275.50 million during the quarter, compared to the consensus estimate of $273.84 million. Prestige Consumer Healthcare had a return on equity of 12.65% and a net margin of 18.97%. The firm’s revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.99 EPS. As a group, research analysts anticipate that Prestige Consumer Healthcare will post 4.18 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the company. Versant Capital Management Inc grew its holdings in shares of Prestige Consumer Healthcare by 38.1% in the 3rd quarter. Versant Capital Management Inc now owns 587 shares of the company’s stock worth $29,000 after acquiring an additional 162 shares during the period. Centiva Capital LP grew its holdings in shares of Prestige Consumer Healthcare by 4.2% in the 4th quarter. Centiva Capital LP now owns 4,174 shares of the company’s stock worth $261,000 after acquiring an additional 167 shares during the period. Meritage Portfolio Management grew its holdings in shares of Prestige Consumer Healthcare by 2.5% in the 4th quarter. Meritage Portfolio Management now owns 7,061 shares of the company’s stock worth $442,000 after acquiring an additional 169 shares during the period. Amalgamated Bank grew its holdings in shares of Prestige Consumer Healthcare by 1.0% in the 3rd quarter. Amalgamated Bank now owns 22,849 shares of the company’s stock worth $1,139,000 after acquiring an additional 222 shares during the period. Finally, CWM LLC grew its holdings in shares of Prestige Consumer Healthcare by 0.9% in the 4th quarter. CWM LLC now owns 24,816 shares of the company’s stock worth $1,553,000 after acquiring an additional 228 shares during the period. Institutional investors and hedge funds own 99.98% of the company’s stock.

Prestige Consumer Healthcare Company Profile

(Get Rating)

Prestige Consumer Healthcare, Inc engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody’s, Beano, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden’s, Monistat, Nix, Pedia-Lax, and Summer’s Eve.